Clinical trials: Progression-Free Survival
Recurrent Cervical Carcinoma, Radiotherapy
Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma
Patients with recurrent or metastatic uterine cervical squamous carcinoma have very poor prognosis. For eligible patients, radiotherapy remains the choice, which has the most effective impact on the survival periods.
- Conditions
- Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor, Nimotuzumab
- Trial name
- NCT04664244
- Testing
- Combination of nimotuzumab and radiotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Lei Li
Lymphocytic Leukemia, Chronic
A Study to Assess the Effect of Maintenance Treatment With Rituximab Versus No Treatment in Participants With Progressive B-Cell Chronic Lymphocytic Leukemia (CLL)
This study will assess the effect of maintenance treatment with rituximab in comparison with observation period (no treatment), in participants with progressive B-cell CLL who have had previous first-line induction treatment with…
- Trial name
- NCT00718549
- Testing
- Cladribine, Cyclophosphamide, Rituximab
- Where
- 6 sites in Belarus, Poland
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Progression-Free-Survival, Recurrence
Clinical Study on Triple Negative Breast Cancer With Chinese Medicine
Breast cancer is one of the most serious threat to women's health of malignant tumors, also the most common causes of cancer death in women.Triple-negative breast cancer (TNBC) refers to the immunohistochemical detection of…
- Conditions
- Progression-Free-Survival, Recurrence, Overall Survival
- Trial name
- NCT03332368
- Testing
- Traditional Chinese medicine
- Where
- 5 sites in China
- Volunteers
- 620 people
- Sponsor
- Sheng Liu
Non-small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Docetaxel and Cisplatin in Patients With Metastatic or Locally Advanced Non-small Cell Lung Cancer
This study assessed the efficacy and safety of Avastin in combination with docetaxel and cisplatin as first-line treatment of patients with metastatic or locally advanced non-small cell lung cancer.
- Trial name
- NCT00661778
- Testing
- Bevacizumab, Cisplatin, Docetaxel
- Where
- 14 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy
At present, it is recommended to continue immunotherapy until progression or unacceptable toxicity. However, only a minority of patients benefits from a durable response and most see the disease progress despite several months of…
- Trial name
- TRAILOCLORI01 (NCT05111197)
- Testing
- SRT, Immunotherapy
- Where
- 5 sites in France
- Volunteers
- 112 people
- Sponsor
- Institut Cancerologie de l'Ouest
Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
Since patients with (borderline) resectable pancreatic cancer have a limited life expectancy, it is important to improve treatment strategies.
- Conditions
- Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-5 (NCT06384560)
- Testing
- Pembrolizumab, Folfirinox, SABR
- Where
- 4 sites in Netherlands
- Volunteers
- 66 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Myeloma (MM)
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
- Trial name
- NCT07029776
- Testing
- teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arkansas
Non-Squamous Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva or placebo, plus platinum-based therapy, as first line treatment in patients with advanced or recurrent non-small cell lung cancer.
- Trial name
- NCT00883779
- Testing
- Platinum chemotherapy (cisplatin or carboplatin), erlotinib [Tarceva], gemcitabine
- Where
- 26 sites in China, Hong Kong and 5 more
- Volunteers
- 451 people
- Sponsor
- Hoffmann-La Roche
Epithelial Ovarian Cancer, Peritoneal Neoplasms
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Background: Birinapant is an experimental cancer treatment drug. It removes certain proteins in cells, which helps to kill the cells.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01681368
- Testing
- Birinapant (TL32711)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Circulating Tumor DNA
IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer
A open label 1:1 randomized phase II exploratory study investigating adjuvant therapy in patients with molecular biologically detectable residual disease after primary resection for localized colorectal tumors.
- Conditions
- Colorectal Cancer, Circulating Tumor DNA, Adjuvant Chemotherapy, Progression Free Survival
- Trial name
- IMPROVE-IT (NCT03748680)
- Testing
- Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy, Intensified Follow-up Schedule
- Where
- 4 sites in Denmark
- Volunteers
- 64 people
- Sponsor
- Karen-Lise Garm Spindler
Prostate Cancer
Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as ketoconazole may stop the production of androgens.
- Trial name
- NCT00027859
- Testing
- docetaxel, estramustine phosphate sodium, ketoconazole
- Where
- 98 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Cancer
Patients' Expectations About the Survival Benefits of Cancer Drugs Approved Based on Progression-Free Survival
This study of current or former cancer patients will evaluate whether communicating data on overall survival data in addition to information on progression-free improves the accuracy of cancer patients' expectations about the…
- Trial name
- NCT07731425
- Testing
- FDA explanation for progression-free survival (control), FDA explanation for progression-free survival with overall survival data, NCI explanation for progression-free survival
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- London School of Economics and Political Science
Metastatic Colorectal Cancer
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
Metastatic colorectal cancer or mCRC is a cancer that starts in the parts of the large intestine (the colon or rectum) and has already spread to other parts of the body.
- Trial name
- NCT07623174
- Testing
- No intervention
- Where
- 10 sites in Poland
- Volunteers
- 110 people
- Sponsor
- Takeda
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Colorectal Cancer, Oligometastatic Disease
RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment including the impact on survival, compared to continued standard first-line systemic…
- Trial name
- RESOLUTE (NCT05862051)
- Testing
- Local Ablative Therapy, Standard first-line systemic treatment
- Where
- 9 sites in Australia
- Volunteers
- 6 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Radiation Toxicity, MRI Simulated Positioning
A Novel Target Delineation Scheme in High-grade Glioma Patients: a Randomized Single-blind Clinical Trial
The main question it aims to answer are: 1. whether the new target delineation scheme can improve Progression-free Survival 2. whether it can reduce the incidence of radiation complications in high-grade glioma patients.
- Conditions
- Radiation Toxicity, MRI Simulated Positioning, High Grade Glioma, Progression-free Survival
- Trial name
- NCT06215495
- Testing
- reduced target volume, EORTC (European organisation for research and treatment of cancer) target volume
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Zhujiang Hospital
Progression-Free Survival
Metformin for the Treatment of mCRC Patients Undergoing FOLFIRI Plus Target Therapy
To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
- Trial name
- NCT06826092
- Testing
- Metformin Pill, FOLFIRI plus target therapy only
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Metastatic Breast Cancer
Breast Cancer Study: Paclitaxel Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment
AIM OF STUDY Primary Efficacy Variable: The primary study objective is the proof of efficacy, measured by progression free survival (PFS) in the treatment of metastatic or locally inoperable recurrent breast cancer.
- Trial name
- PASO (NCT01320111)
- Testing
- Paclitaxel and Sorafenib, Paclitaxel
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic…
- Trial name
- KEYNOTE-B84 (NCT04815720)
- Testing
- pepinemab + pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vaccinex Inc.
Stage II A/B Seminomatous Germ Cell Tumors
Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST)
Primary objective: to evaluate progression-free survival in patients with clinical stage II A/B seminomatous germ cell tumor undergoing primary retroperitoneal lymph node dissection (RPLND) without adjuvant treatment Secondary…
- Trial name
- NCT02797626
- Testing
- Primary retroperitoneal lymph-node dissection (pRPLND)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Heinrich-Heine University, Duesseldorf